Pernix Therapeutics to Report Second Quarter 2013 Financial Results on
August 9, 2013
Management to Host a Conference Call on August 9, 2013 at 9:00 a.m. EDT
THE WOODLANDS, Texas -- July 30, 2013
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical
company, today announced that it will release its second quarter 2013
financial results before the U.S. stock market opens on Friday, August 9, 2013
and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the
The conference call will feature remarks by Michael Pearce, Chairman of the
Board, President, and Chief Executive Officer, and Tracy Clifford, Vice
President of Accounting and Corporate Controller. To participate in the
conference call, please dial (877) 312-8783 (domestic) or (408) 940-3874
(international). Participants can reference the passcode 18730492. Please dial
in approximately 5 minutes prior to the call.
The conference call will also be available via a live listen-only webcast and
can be accessed through the Investor Relations section of the Company’s
website www.pernixtx.com. Please allow extra time prior to the call to visit
the Company’s website and download any software that may be needed to listen
to the webcast.
A replay of the conference call will be available through August 16, 2013, at
(855) 859-2056 domestic and (404) 537-3406 international. The passcode for the
replay is 18730492. An online archive of the webcast will be available on the
Company’s website following the conference call.
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded
products, including the recently acquired Hawthorn Pharmaceuticals’ product
line. The Company’s branded products for the pediatrics market include CEDAX®,
an antibiotic for middle ear infections, NATROBA™, a topical treatment for
head lice marketed under an exclusive co-promotion agreement with ParaPRO,
LLC, and ZUTRIPRO® of treatments for cough and cold. The Company’s branded
products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for
H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend
to promote dietary management. The Company also markets the branded product,
SILENOR®, for the treatment of insomnia. The Company promotes its branded
pediatric and gastroenterology products through its sales force. Pernix
markets its generic products through its wholly-owned subsidiaries, Cypress
Pharmaceutical and Macoven Pharmaceuticals. The Company’s wholly-owned
subsidiary, Pernix Manufacturing, manufactures and packages products for the
pharmaceutical industry in a wide range of dosage-forms.
Additional information about Pernix is available on the Company’s website
located at www.pernixtx.com.
Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, (800) 793-2145 ext. 3002
Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.